Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data (1509)
Colin Dayan(University of Birmingham), Peter Senior(University of Alberta), Sashiananthan Ganesananthan(Cardiff University), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Sven G. Meuth(University Hospital Münster), Ilaria Muller(University of Milan), Nadia Daizadeh, Hans‐Peter Hartung(The University of Sydney), Elizabeth M. Poole(St. Elizabeth's Hospital), Christopher LaGanke(Urology Associates), Eva Havrdová(Charles University), Bart Van Wijmeersch(National MS Center Melsbroek), Darren P. Baker(Biogen (United States)), Salman Afsar, David Margolin(Sanofi (United States)), Beatriz Lecumberri(Hospital Universitario La Paz), Tjalf Ziemssen(University Hospital Carl Gustav Carus), Samuel F. Hunter(Advanced Neurosciences Institute)
Cited by 0
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k